Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 in Advanced Biliary Tract Cancer
NCT06413745Phase 2Active, not recruiting
- Sponsor
- Hengrui
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in biliary tract cancer (BTC), sponsored by Hengrui. Started Jun 2024; status: active, not recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06413745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06413745.